Literature DB >> 13338887

Clinical and laboratory studies of novobiocin, a new antibiotic.

W M KIRBY, D G HUDSON, W D NOYES.   

Abstract

Entities:  

Keywords:  ANTIBIOTICS/therapeutic use

Mesh：

Substances：

Year:  1956        PMID： 13338887     DOI： 10.1001/archinte.1956.00250250007001

Source DB:  PubMed          Journal:  AMA Arch Intern Med        ISSN： 0888-2479


× No keyword cloud information.
  11 in total

1.  Efficacy of short courses of oral novobiocin-rifampin in eradicating carrier state of methicillin-resistant Staphylococcus aureus and in vitro killing studies of clinical isolates.

Authors:  E G Arathoon; J R Hamilton; C E Hench; D A Stevens
Journal:  Antimicrob Agents Chemother       Date:  1990-09       Impact factor: 5.191

Review 2.  Challenges of antibacterial discovery.

Authors:  Lynn L Silver
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

3.  Steady-state serum pharmacokinetics of novobiocin and rifampin alone and in combination.

Authors:  G L Drusano; R J Townsend; T J Walsh; A Forrest; E J Antal; H C Standiford
Journal:  Antimicrob Agents Chemother       Date:  1986-07       Impact factor: 5.191

4.  Potent antiviral activity of topoisomerase I and II inhibitors against Kaposi's sarcoma-associated herpesvirus.

Authors:  Lorenzo González-Molleda; Yan Wang; Yan Yuan
Journal:  Antimicrob Agents Chemother       Date:  2011-11-21       Impact factor: 5.191

5.  Randomized double-blinded trial of rifampin with either novobiocin or trimethoprim-sulfamethoxazole against methicillin-resistant Staphylococcus aureus colonization: prevention of antimicrobial resistance and effect of host factors on outcome.

Authors:  T J Walsh; H C Standiford; A C Reboli; J F John; M E Mulligan; B S Ribner; J Z Montgomerie; M B Goetz; C G Mayhall; D Rimland
Journal:  Antimicrob Agents Chemother       Date:  1993-06       Impact factor: 5.191

6.  Biological activities of novel gyrase inhibitors of the aminocoumarin class.

Authors:  Christine Anderle; Martin Stieger; Matthew Burrell; Stefan Reinelt; Anthony Maxwell; Malcolm Page; Lutz Heide
Journal:  Antimicrob Agents Chemother       Date:  2008-03-17       Impact factor: 5.191

7.  Antimicrobial and DNA gyrase-inhibitory activities of novel clorobiocin derivatives produced by mutasynthesis.

Authors:  Ute Galm; Stefanie Heller; Stuart Shapiro; Malcolm Page; Shu-Ming Li; Lutz Heide
Journal:  Antimicrob Agents Chemother       Date:  2004-04       Impact factor: 5.191

8.  Structure-Activity Studies with Bis-Amidines That Potentiate Gram-Positive Specific Antibiotics against Gram-Negative Pathogens.

Authors:  Charlotte M J Wesseling; Cornelis J Slingerland; Shanice Veraar; Samantha Lok; Nathaniel I Martin
Journal:  ACS Infect Dis       Date:  2021-11-12       Impact factor: 5.084

9.  Watching DNA Replication Inhibitors in Action: Exploiting Time-Lapse Microfluidic Microscopy as a Tool for Target-Drug Interaction Studies in Mycobacterium.

Authors:  Damian Trojanowski; Marta Kołodziej; Joanna Hołówka; Rolf Müller; Jolanta Zakrzewska-Czerwińska
Journal:  Antimicrob Agents Chemother       Date:  2019-09-23       Impact factor: 5.191

Review 10.  Development of Small-Molecule Inhibitors Against Zika Virus Infection.

Authors:  Lili Wang; Ruiying Liang; Yaning Gao; Yanbai Li; Xiaoqian Deng; Rong Xiang; Yina Zhang; Tianlei Ying; Shibo Jiang; Fei Yu
Journal:  Front Microbiol       Date:  2019-12-06       Impact factor: 5.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.